Loading clinical trials...
Loading clinical trials...
Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial
Conditions
Interventions
Tisagenlecleucel
Blinatumomab
+1 more
Start Date
June 5, 2020
Primary Completion Date
October 8, 2025
Completion Date
January 7, 2026
Last Updated
July 9, 2020
NCT05376111
NCT04065399
NCT05453500
NCT07295951
NCT03970096
NCT05292664
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions